Abarceo Pharma is developing small molecule therapeutics that target the voltage-dependent anion channel 1 (VDAC1) on beta cells to restore their function in Type 2 Diabetes patients. This approach aims to reverse beta cell dysfunction, enabling natural insulin production and addressing the critical need for effective disease-modifying treatments in diabetes management.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In Type 2 Diabetes, beta cell dysfunction leads to impaired insulin production, requiring treatments that address the underlying cause rather than just managing symptoms. Current therapies often fail to restore natural insulin production, leaving a critical need for disease-modifying treatments.
Solution
Abarceo Pharma is developing small molecule therapeutics that target the voltage-dependent anion channel 1 (VDAC1) on beta cells to restore their function. By inhibiting dysfunctional VDAC1, the therapeutics aim to revert beta cells from a dysfunctional state to a functional state, preserving beta cell function and enabling patients to produce insulin naturally. This approach targets the root cause of beta cell dysfunction, offering a potential disease-modifying treatment for Type 2 Diabetes. The company is also exploring the potential of VDAC1 modulation in other mitochondrial diseases like cardiovascular disease and dementia.
Target Audience
The primary target audience includes Type 2 Diabetes patients and healthcare professionals seeking disease-modifying treatments, as well as individuals with other mitochondrial diseases like cardiovascular disease and dementia.
Features
- Small molecule therapeutics designed to inhibit VDAC1, a key mitochondrial protein regulating energy production in cells.
- Focus on restoring beta cell function in Type 2 Diabetes patients, enabling natural insulin production.
- Potential application in other mitochondrial diseases, including cardiovascular disease and dementia.
- Patented small molecules that restore beta-cell function by inhibiting dysfunctional VDAC1.
- Preclinical Proof of Concept studies in animal models of T2D, Alzheimer’s Disease (AD), and acute myocardial infarction (AMI).